- Home
- SUZ vs EXEL Comparison
SUZ vs EXEL Comparison
Compare SUZ & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUZ
- EXEL
- Stock Information
- Founded
- SUZ 1924
- EXEL 1994
- Country
- SUZ Brazil
- EXEL United States
- Employees
- SUZ N/A
- EXEL N/A
- Industry
- SUZ Paper
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SUZ Basic Materials
- EXEL Health Care
- Exchange
- SUZ Nasdaq
- EXEL Nasdaq
- Market Cap
- SUZ 11.5B
- EXEL 12.0B
- IPO Year
- SUZ N/A
- EXEL 2000
- Fundamental
- Price
- SUZ $10.14
- EXEL $37.83
- Analyst Decision
- SUZ
- EXEL Buy
- Analyst Count
- SUZ 0
- EXEL 21
- Target Price
- SUZ N/A
- EXEL $44.00
- AVG Volume (30 Days)
- SUZ 2.0M
- EXEL 3.8M
- Earning Date
- SUZ 08-19-2025
- EXEL 07-28-2025
- Dividend Yield
- SUZ 2.65%
- EXEL N/A
- EPS Growth
- SUZ N/A
- EXEL 81.76
- EPS
- SUZ 1.16
- EXEL 2.08
- Revenue
- SUZ $9,414,799,585.00
- EXEL $2,230,005,000.00
- Revenue This Year
- SUZ $9.38
- EXEL $9.88
- Revenue Next Year
- SUZ $16.94
- EXEL $12.59
- P/E Ratio
- SUZ $8.10
- EXEL $18.01
- Revenue Growth
- SUZ 30.47
- EXEL 10.73
- 52 Week Low
- SUZ $8.41
- EXEL $24.26
- 52 Week High
- SUZ $10.98
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- SUZ 66.33
- EXEL 35.37
- Support Level
- SUZ $9.10
- EXEL $36.37
- Resistance Level
- SUZ $10.05
- EXEL $37.81
- Average True Range (ATR)
- SUZ 0.19
- EXEL 1.25
- MACD
- SUZ 0.07
- EXEL -0.52
- Stochastic Oscillator
- SUZ 86.39
- EXEL 14.60
About SUZ Suzano S.A.
Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.